文献速递前列腺癌

基于磁共振成像的前列腺癌多灶性与局灶治疗候选资格

Multifocality of Prostate Cancer and Candidacy for Focal Therapy Based on Magnetic Resonance Imaging.
PubMed 文献 · Urology · 2022-07-29

在2015-2021年前瞻性PLUM前列腺活检队列中,897例无前列腺癌病史且PI-RADS≥3的男性接受mpMRI及靶向和系统活检。28.7%为单一靶向活检确诊病灶,10.4%为多灶性;仅6.8%(61/897)在GG限制后仍为局灶治疗潜在候选者。

要点

  • mpMRI显示50.2%为单发病灶、15.7%为单侧多灶、34.1%为双侧病灶。
  • 单一靶向活检确诊患者中35.8%(92/257)存在mpMRI未检测到的对侧前列腺癌。
  • 系统活检使单一确诊病灶比例从28.7%降至18.4%,多灶性从10.4%升至20.6%。

核心结论

  • 在临床怀疑前列腺癌并接受mpMRI的男性中,28.7%有单一靶向活检确诊病灶,10.4%在mpMRI上呈多灶性,但许多mpMRI未检测到的对侧前列腺癌被发现。
  • 仅6.0%的活检初治男性仍为单一GG2 mpMRI病灶、可能适合局灶治疗。

研究设计与样本

  • 前瞻性Loyola泌尿科mpMRI(PLUM)前列腺活检队列,纳入2015-2021年无前列腺癌病史、接受mpMRI及靶向和系统前列腺活检的男性。
  • 共897例PI-RADS≥3病灶患者,按mpMRI病灶位置、靶向活检和系统活检进行分类。
  • 单一活检确诊GG2病灶且系统活检一致者定义为局灶治疗候选者;采用多变量逻辑回归评估mpMRI未检测到对侧前列腺癌的预测因素。

主要发现

  • 897例中,450例(50.2%)为单发mpMRI病灶,141例(15.7%)为单侧多发病灶,306例(34.1%)为双侧病灶。
  • 28.7%有单一靶向活检确诊病灶,10.4%为多灶性。
  • 单一靶向活检确诊患者中,92/257(35.8%)存在mpMRI未检测到的对侧前列腺癌,DRE、PSA和活检史为独立预测因素。
  • 系统活检使单一确诊病灶比例从28.7%降至18.4%,多灶性前列腺癌从10.4%升至20.6%。
  • 经GG限制后,61/897(6.8%)仍为潜在局灶治疗候选者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the prevalence of multiparametric magnetic resonance imaging (mpMRI)-detected and targeted biopsy-confirmed multifocal and unifocal prostate cancer (PCa) among patients with Prostate Imaging Reporting and Data System (PI-RADS) ≥3 lesions. Focal therapy (FT) options for PCa are tied to accurate spatial identification on mpMRI. METHODS: Men without prior diagnosis of PCa receiving mpMRI, targeted and systematic prostate biopsy in the Prospective Loyola Urology mpMRI (PLUM) Prostate Biopsy Cohort from 2015-2021 were included. Patients with PI-RADS ≥3 lesions were classified by mpMRI lesion location, targeted biopsy, and systematic biopsy. Patients with single biopsy-confirmed grade group (GG) 2 lesions and concordant systematic biopsy were defined as FT candidates. Multivariable logistic regression evaluated predictors of mpMRI-undetected contralateral PCa. RESULTS: Of 897 patients, 450 (50.2%) had a single, 141 (15.7%) had multiple unilateral, and 306 (34.1%) had bilateral mpMRI lesions. 28.7% had a single targeted biopsy-confirmed lesion while 10.4% were multifocal. Among single targeted biopsy-confirmed patients, 92/257 (35.8%) had contralateral PCa missed by mpMRI with DRE, PSA, and biopsy history identified as independent predictors. Systematic biopsy findings dropped the rate of single confirmed lesions from 28.7% to 18.4% and multifocal PCa increased from 10.4% to 20.6%. After GG restrictions, 61/897 (6.8%) remained potential FT candidates. CONCLUSIONS: Among men with clinical suspicion of prostate cancer receiving mpMRI, 28.7% had a single targeted biopsy-confirmed lesion and 10.4% had multifocality on mpMRI, but many mpMRI-undetected contralateral PCa were identified. Only 6.0% of biopsy-naïve men remained with a single GG2 mpMRI lesion potentially amenable to FT.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Okabe Y, Patel HD, Rac G, et al. Multifocality of Prostate Cancer and Candidacy for Focal Therapy Based on Magnetic Resonance Imaging. Urology. 2022. PMID: 35914584. doi:10.1016/j.urology.2022.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。